, which is required for TGF-b-induced growth arrest in these cells, is not maintained. Moreover, we show that artificially attenuating the TGF-b-Smad signaling pathway in HaCaT cells is sufficient to prevent TGF-b-induced growth arrest. Our results demonstrate that the duration of TGF-b-Smad signaling is a critical determinant of the specificity of the TGF-b response.
Introduction
Transforming growth factor-b (TGF-b) plays a complex role in tumorigenesis, since it has both tumor suppressive and oncogenic activities (Akhurst and Derynck et al., 2001; Wakefield and Roberts, 2002) . At early stages it acts as a tumor suppressor. This is thought to be predominantly through its ability to induce growth arrest and apoptosis in epithelial cells from which the majority of human cancers derive. Additional functions of TGF-b that might be relevant for its tumor suppressive effects include its roles in maintenance of genomic stability, induction of replicative senescence and suppression of telomerase activity, which are observed in certain cell types (Wakefield and Roberts, 2002) . At late stages, tumor cells become resistant to the antiproliferative effects of TGF-b, but often remain responsive to TGF-b signaling, and frequently secrete TGF-b. For example, pancreatic tumors overexpress all the three TGF-b isoforms and this correlates with decreased patient survival (Friess et al., 1993) . In late stage tumors, the pro-oncogenic activites of TGF-b dominate. TGF-b acts directly on the tumor cells to induce epithelial to mesenchymal transition (EMT), and to increase motility, invasiveness and metastasis, and on the surrounding stroma to suppress immune surveillance and increase angiogenesis (Akhurst and Derynck et al., 2001; Wakefield and Roberts, 2002) .
TGF-b signals through a heterotetrameric receptor complex comprising type II receptors (TbRII) and type I receptors (TbRI/ALK5), both serine/threonine kinases (Massague´and Wotton, 2000) . Downstream of the receptors, the Smads act as major transducers of the signal from the receptors to the nucleus. The receptorregulated Smads (R-Smads), Smad2 and 3, are directly phosphorylated by the type I receptor and form complexes with the common mediator Smad (co-Smad; Smad4) that accumulate in the nucleus and directly activate target genes in conjunction with other transcription factors (Massague´and Wotton, 2000) . Smadindependent signaling also occurs in response to TGF-b, in particular activation of mitogen-activated protein (MAP) kinase pathways, phosphoinositide 3-kinase (PI3K) and PP2A/p70S6K, but the mechanisms by which this occurs are not fully understood (Massagueé t al., 2000; Wakefield and Roberts, 2002) . After prolonged signaling, the TGF-b receptors are degraded via the proteosomal and lysosomal pathways by a mechanism involving the recruitment to the activated receptor complexes of E3 ubiquitin ligases Smurf1 and Smurf2 by the inhibitory Smad, Smad7 (Kavsak et al., 2000; Ebisawa et al., 2001) . Correlating well temporally with receptor degradation, the activated Smads have been shown to become dephosphorylated and to reappear in the cytoplasm after prolonged TGF-b signaling . TGF-b is thought to induce a G 1 cell cycle arrest through transcriptional induction of CDK inhibitors, p15 INK4B and in some cell types, p21
Cip1/WAF1
, and downregulation of the CDK-activating phosphatase, Cdc25A (Massague´et al., 2000) . When p15 INK4B is absent, p21
Cip1/WAF1 appears to fulfil its function (Florenes et al., 1996) . The result is inhibition of cyclin/CDK complexes, leading to accumulation of the hypophosphorylated form of the retinoblastoma-susceptibility gene product, pRb (Massague´et al., 2000) . TGF-b-induced downregulation of c-myc also plays a critical role in TGF-binduced growth arrest, since it is important for activation of both p15 INK4B and p21 Cip1/WAF1 by TGF-b (Claassen and Hann, 2000; Seoane et al., 2001; Staller et al., 2001) . Understanding the molecular mechanisms whereby tumor cells specifically become resistant to TGF-b-induced growth arrest is obviously important for understanding tumor formation and for developing therapeutic strategies. Loss of the ability of cells to downregulate c-myc expression in response to TGF-b has been shown to be important for confering resistance to TGF-b-induced growth arrest in the breast cancer cell line MDA-MB231 (Chen et al., 2001) . However, it is not clear whether this mechanism operates in other tumor cells. Much emphasis has been given to the loss of components of the TGF-b signaling pathway, in particular TbRII and Smad4, as a mechanism for cells acquiring resistance to the antiproliferative effects of TGF-b and hence a growth advantage. However, considering all human tumors, these defects are relatively rare. Smad4 is frequently mutated or deleted in pancreatic and colon tumors, though not in other tumor types, and moreover, loss of Smad4 does not always lead to loss of TGF-b-induced growth arrest (Dai et al., 1999; Fink et al., 2001 ; see also Sirard et al., 2000) . Loss of TbRII occurs in colon and gastric cancers, usually in conjunction with defects in DNA replication error repair Akhurst and Derynck, 2001; Derynck et al., 2001) . This would be expected to inhibit all TGF-b signaling and would not account for specific loss of TGF-b-induced growth arrest. A more frequent observation is that levels of the TGF-b receptors are decreased in advanced human tumors (Baldwin et al., 1996; Wagner et al., 1998; Kim et al., 2000; Derynck et al., 2001; Jonson et al., 2001 ).
Here we have investigated how pancreatic tumor cells specifically evade TGF-b-induced growth arrest, while maintaining other TGF-b responses. The results show that in pancreatic tumor cells that contain a full complement of Smads but are nevertheless resistant to TGF-b-induced growth arrest, the TGF-b/Smad signaling pathway is attenuated, compared with epithelial cells that are sensitive to the antiproliferative effects of TGFb. The attenuated pathway correlates with low levels of TGF-b type I receptor and results in an altered expression profile of TGF-b-inducible genes required for cell cycle arrest. We show that this can account for the specific loss of TGF-b-induced growth arrest. Our data demonstrate that the duration of TGF-b-Smad signaling is a critical determinant of the specificity of the TGF-b response, and suggest that signal duration may be modulated during tumor progression.
Results

Characterization of the cell lines
We studied the TGF-b signaling pathway in a panel of tumor cell lines derived from pancreatic ductal adenocarcinomas, to determine which of the endogenous responses to TGF-b were preserved in these cells. Some of the cell lines had lost Smad4; others were Smad4-positive (Table 1) . For comparison, we also included two other well-characterized cell lines: the immortalized nontransformed keratinocyte epithelial cell line, HaCaT, which is Smad4-positive (Hannon and Beach, 1994; Pierreux et al., 2000) , and the Smad4-null breast epithelial cell line, MDA-MB468 .
As an initial characterization of these cell lines, we investigated whether they all exhibited an epithelial phenotype. From phase-contrast images, four of the cell lines (HaCaT, grew as well-defined epithelial sheets (Figure 1a) . Consistent with this, E-cadherin was expressed at their adherens junctions (Figure 1a ; Hay, 1995) . Two of the cell lines HaCaT (S)
The origin of the human cells is indicated as (S) skin, (B) breast and (P) pancreas. a Smad4 and b CDKN2A (p16) genotypes (Hannon and Beach, 1994; Hahn et al., 1996; Schutte et al., 1996; Kleeff and Korc, 1998; Stott et al., 1998; Moore et al., 2001; Sirivatanauksorn et al., 2001 Figure 1a ). Two other cell lines (PT45 and Panc-1) appeared to have lost their adherens junctions, as seen by a complete loss of E-cadherin staining, and their scattered appearance in the phase contrast images (Figure 1a ). Loss of E-cadherin in tumor cells is often associated with an epithelial to mesenchymal transition (Hay, 1995) , and consistent with this, these cells strongly expressed the mesenchymal marker, vimentin ( Figure 1a) . The E-cadherin and vimentin staining was confirmed by Western blotting (Figure 1b) .
Only HaCaT and Colo-357 cells growth arrest in response to TGF-b
When stimulated with TGF-b, epithelial cells arrest in the G 1 phase of the cell cycle (Massague´et al., 2000) . We therefore tested these cell lines for their ability to be growth arrested by TGF-b, comparing the cell cycle profiles of these cells in the presence and absence of TGF-b, with those resulting from serum starvation ( Figure 1c ). When HaCaT cells were stimulated with TGF-b, the majority of the cells accumulated in G 1 , and a similar response was seen upon serum starvation. Colo-357 cells behaved similarly, although the effect was not as strong . None of the other cell lines showed any substantial accumulation of cells in G 1 in response to TGF-b, although BxPC3 has been previously reported to undergo a partial TGF-b-induced growth arrest (Dai et al., 1999) . The results were confirmed in cell-counting assays over a 72-h period (data not shown). In two of the cell lines (SW-979 and MDA-MB468), no growth arrest was seen even upon serum starvation, suggesting that key components of the cell cycle regulatory machinery are missing in these cells. Consistent with this, both cell lines (though not any of the others) have lost the critical component of the cell cycle machinery, pRb (Table 1; Stott et al., 1998) .
Some of the pancreatic tumor cells have lost components of the TGF-b signaling pathway
To understand to what extent the lack of cell cycle arrest in response to TGF-b was due to loss of components of the TGF-b signaling pathway, we investigated the levels of the co-Smad, Smad4 and R-Smads, Smad2 and 3 in these cells (Figure 2a ). These were compared with the levels of Smads in HaCaT and MDA-MB468 cells. Of the pancreatic cell lines, Smad4 was present in Colo-357, PT45 and Panc-1 cell lines, but absent in BxPC3, CFPac1 and SW-979 cells (Figure 2a) . This confirmed what was expected from the genotypes at 18q21, except for . In (a), cells were processed for immunofluorescence using anti-E-cadherin (a-E-cad) or anti-vimentin (a-vim) antibodies. Samples were examined by confocal laser scanning microscopy. Phase-contrast images (ph. con.) of the same fields are also shown. In (b), whole cell extracts were analysed by Western blotting using antibodies against E-cadherin, vimentin and GRB2 (as a loading control). (c) TGF-b stimulation of cell cycle arrest in the different cell lines. Actively growing low confluency cells (40-50%) were either untreated or treated with 2 ng/ml of TGF-b1 for 24 h, except in the case of Colo-357, which were assayed after 15 h. In each case a parallel cell population was serum starved (SS) in media minus FCS for 36 h as a control for cell cycle arrest. Samples were analysed by FACS to determine the number of cells in G 1 (black bar), S (white bar) or G 2 /M (gray bar)
Attenuated TGF-b-Smad signaling in tumor cells FJ Nicolás and CS Hill SW-979 cells, which have been described as wild-type for Smad4 Sirivatanauksorn et al., 2001) . No Smad4 was detected in this cell line at the protein or mRNA level, but genomic analysis by PCR confirmed the presence of all the exons for Smad4 (data not shown), suggesting that the lack of Smad4 expression could be due to a gene-silencing phenomenon. Analysis of the levels of the R-Smads, Smad2 and 3 with an antibody that specifically recognizes both, indicated that all the cell lines expressed Smad2, although at very different levels, and all except Colo-357, SW-979 and MDA-MB468 expressed detectable levels of Smad3 ( Figure 2a Upon TGF-b stimulation, Smad2 and 3 are phosphorylated and accumulate in the nucleus within 1 h (Massague´and Wotton, 2000; Pierreux et al., 2000) . As an indication of the ability of these cell lines to respond to TGF-b, and hence provide confirmation of the presence of functional TGF-b receptors, we investigated TGF-b-induced translocation of Smad2 and 3 by immunofluorescence . With the exception of CF-Pac1, Smad2/3 clearly translocated to the nucleus in 1 h in all the cell lines ( Figure 2b ). Interestingly, this occurred regardless of the presence or absence of Smad4, demonstrating that this process is Smad4-independent (Liu et al., 1997) . Further analysis of CF-Pac1 cells indicated that they do express both (2 ng/ml) for 1 h. Whole cell extracts (35 mg) were analysed by Western blotting using antibodies against Smad4, Smad2/3, Smad3 and GRB2 as a loading control. (b) Cells were either unstimulated or stimulated with TGF-b1 (2 ng/ml) for 1 h. Samples were processed for immunofluorescence using an anti-Smad2/3 antibody and examined by confocal laser scanning microscopy Attenuated TGF-b-Smad signaling in tumor cells FJ Nicolás and CS Hill receptors (data not shown; Goggins et al., 1998) ; their complete lack of responsiveness to TGF-b suggests that one or both receptors may be mutated.
Taken together with the data in the previous section, it is evident that there is no simple correlation between resistance to TGF-b-induced growth arrest and loss of components of the TGF-b signaling pathway. Most importantly though, we have identified two cell lines, PT45 and Panc-1, which have a full complement of Smad2, Smad3 and Smad4, and functional TGF-b receptors, as indicated by the translocation of the RSmads to the nucleus upon TGF-b induction, but nevertheless are resistant to TGF-b-induced growth arrest. These cells, however, do growth arrest upon serum starvation, indicating that the machinery required for cell cycle arrest is intact.
PT45 and Panc-1 cells exhibit an altered expression profile of TGF-b-inducible genes required for cell cycle arrest
To understand the mechanism whereby PT45 and Panc-1 cells are resistant to TGF-b-induced growth arrest, we investigated the ability of these cells to regulate a panel of genes in response to TGF-b. The panel included genes involved in TGF-b-induced growth arrest, the CDK inhibitors, p21 WAF1/Cip1 (hereafter, p21) (Datto et al., 1995; Reynisdottir et al., 1995) , and p15 INK4B (hereafter p15) (Hannon and Beach, 1994), the CDK-activating phosphatase, Cdc25A (Iavarone and Massague´, 1997) and the transcription factor JunB, which has also been shown recently to be involved in suppression of cell proliferation (Passegue and Wagner, 2000) . In addition, the panel contained another AP-1 family member c-Jun (Pertovaara et al., 1989) , which is implicated in autocrine production of TGF-b (Kim et al., 1990) , the inhibitory Smad, Smad7 (Nakao et al., 1997) , which is upregulated in some human pancreatic tumors (Kleeff et al., 1999) and plasminogen activater inhibitor 1 (PAI-1), which is involved in extracellular matrix production in response to TGF-b and in cellular invasiveness (Laiho et al., 1986; Kleeff et al., 1999; Rowland-Goldsmith et al., 2001) . We compared the TGF-b responses of PT45 and Panc-1 cells with those of HaCaT and Colo-357 cells which are Smad4-positive and do undergo a cell cycle arrest in response to TGF-b, and those of BxPC3 cells which are Smad4-null and are resistant to TGF-b-induced growth arrest.
The responses of HaCaT and Colo-357 cells to TGF-b were very similar. In both, TGF-b strongly induced the expression of p21, JunB, c-Jun, Smad7 and PAI-1 all within 1 h of TGF-b stimulation (Figure 3) . The induction of p15 in both cell lines was weaker and delayed relative to the induction of p21 (Figure 3 ). Both cell lines exhibited a downregulation of Cdc25A 15 h after TGF-b stimulation. In contrast, the responses of PT45 and Panc-1 cells were very different. Firstly, no p15 induction was seen in either cell line, and since not even basal levels were detected, it is likely that this gene is deleted in these cells along with the adjacent gene, p16 INK4A ( Figure 3 ; Table 1 An initial normal accumulation of phosphorylated Smad2 in the nucleus upon TGF-b stimulation was observed, but the levels of nuclear phosphorylated Smad2 disappeared abruptly after 1 and 2 h, respectively (top panel). The kinetics of nuclear accumulation of Smad4 were investigated using the same extracts. In unstimulated cells, some Smad4 is already present in the nucleus , and its kinetics of accumulation in the nucleus exactly mirrored the accumulation of phosphorylated Smad2 (middle panel). Thus, the TGF-b-Smad signaling pathway was attenuated in PT45 and Panc-1 cells compared with HaCaT and Colo-357 cells. We confirmed the kinetics of nuclear accumulation of the Smads using immunofluorescence (Figure 4b ). The temporal patterns of nuclear accumulation of Smad2/3 in this assay for the different cell types agreed extremely well with the results obtained from the cell fractionation experiments.
To investigate the accumulation of activated Smad3 in the nucleus upon TGF-b stimulation directly, the same nuclear extracts were assayed by bandshift assay for the presence of a Smad3/Smad4 complex that binds the Smad binding element (SBE) from the c-Jun 5 0 UTR in a TGF-b-inducible manner (Wong et al., 1999) . Again it was evident that the TGF-b signaling pathway was attenuated in PT45 and Panc-1 cells. The nuclear Smad3/Smad4 complex disappeared abruptly after 1 and 2 h, respectively in these cell lines (Figure 4c) . In HaCaT cells, the complex was still readily detectable at the 6-h time point. The Smad3/Smad4 complex in Colo-357 cells was weak, probably due to the low levels of Smad3; however, it still persisted longer than that in PT45 and Panc-1 cells (Figure 4c ). The presence of both Smad3 and 4 in these complexes was confirmed by supershifts using anti-Smad3 and anti-Smad4 antibodies (data not shown).
PT45 and Panc-1 cells contain low levels of TGF-b type I receptor protein
We next investigated the molecular mechanism underlying the attenuated TGF-b-Smad pathway in PT45 and Panc-1 cells. Previous work has suggested that high levels of ERK activity can influence the ability of activated Smads to accumulate in the nucleus (Kretzschmar et al., 1999) . However, we found no correlation between the levels of activated ERK and duration of Smad signaling in any of the cell lines investigated (data not shown).
Recent work has demonstrated that the TGF-b signaling pathway is terminated via receptor degradation (Kavsak et al., 2000; Ebisawa et al., 2001) . This is thought to occur through the recruitment of an E3-ubiquitin ligase (Smurf1 or 2) by Smad7 to the activated receptor complex, and subsequent degradation of the receptors and Smad7 via the proteasome. We have very recently demonstrated that during active TGF-b signaling, constant nucleocytoplasmic shuttling of the Smads provides a mechanism whereby the Smads continuously monitor receptor activity (Inman et al., 2002b) . This means that at all times, the concentration of active Smads in the nucleus can be directly dictated by the levels of activated receptors in the cytoplasm. Importantly, it explains how the overall time that the active Smads reside in the nucleus will be dictated by the time that the receptors remain active. The duration of the signaling pathway therefore appears to be determined by the time taken for the receptors to degrade and fall below a threshold level required for active signaling. Premature termination of the TGF-b-Smad signaling pathway in PT45 and Panc-1 cells might thus result either from low initial levels of the receptors in these cells or increased rates of degradation following TGF-b stimulation.
We therefore investigated the levels of receptors in these cells. It was clear that PT45 and Panc-1 cells contained much lower levels of TbRI/ALK5 than the other three cell types, when equal numbers of cells were analysed by Western blotting ( Figure 5 ). Consistent with the low levels of TbRI/ALK5 in PT45 and Panc-1 cells, the amount of Smad2 phosphorylated after a 30-min TGF-b stimulation was substantially lower than in the other cells which express higher levels of TbRI/ALK5. This was independent of the levels of Smad2 ( Figure 5 ).
We also assayed the levels of Smad7 in these cells, reasoning that overexpression of Smad7 could be an additional mechanism whereby the receptors might degrade more rapidly in PT45 and Panc-1 cells, resulting in attenuation of the signaling pathway. Panc-1 cells Figure 5 PT45 and Panc-1 cells express low levels of TbRI/ALK5 protein. Cells were either uninduced or induced with 2 ng/ml of TGF-b1 for 30 min, and whole cell extracts were then analysed for the presence of TbRI/ALK5, Smad7, phosphorylated Smad2, Smad2 and 3, and GRB2 protein by Western blotting. In some cell lines (HaCaT, Colo-357, and BxPC3), TbRI runs as a doublet. Both bands were confirmed as corresponding to TbRI in these cells by competition experiments using the peptide to which the antibody was raised (data not shown). The faster migrating band may be the receptor that is incompletely glycosylated (Wells et al., 1997) . Note that the Smad2/3 lane for the TGF-b-induced BxPC3 sample (lane 10) is underloaded Attenuated TGF-b-Smad signaling in tumor cells FJ Nicolás and CS Hill exhibit high levels of Smad7 relative to the other cell lines ( Figure 5 ; Kleeff et al., 1999) , which might affect the rate of receptor degradation in these cells. However, PT45 cells do not express high levels of Smad7, indicating that overexpression of Smad7 is not likely to be responsible for attenuation of the signaling pathway in PT45 cells. Taken together, these data suggest that the attenuated signaling pathway observed in PT45 and Panc-1 cells could result from the low levels of TbRI/ALK5 protein.
Expression of p21 protein is not maintained in PT45 and Panc-1 cells
We have demonstrated that PT45 and Panc-1 cells, which contain a full complement of Smads, do not growth arrest in response to TGF-b, and exhibit an attenuated TGF-b signaling pathway. To understand whether the attenuated signaling pathway was responsible for the resistance to TGF-b -induced growth arrest, we investigated the TGF-b-induced expression of p21 in more detail. p21 expression is not only regulated at the level of transcription, but also by proteasome-dependent degradation, and as a result has a short half-life (B1 h) (Touitou et al., 2001) . Cells that growth arrest upon TGF-b stimulation (HaCaT and Colo-357) showed strong inductions of p21 protein at 2.5 and 7 h after TGF-b stimulation (Figure 6a ) and p21 protein was still readily detectable in the nuclei of these cells 16 h post-TGF-b stimulation (Figure 6b ). PT45 and Panc-1 cells, however, that have an attenuated TGF-b signaling pathway, exhibit only a weak induction of p21 and expression of p21 protein is not sustained in these cells (Figure 6a and b) .
Overexpression of p21 or activated ALK5 in PT45 and Panc-1 cells leads to accumulation of cells in the G 1 phase of the cell cycle Our data suggest that the attenuation of the TGF-bSmad signaling pathway in PT45 and Panc-1 cells, which may be a consequence of low levels of ALK5, results in only transient upregulation of genes such as p21, that are involved in growth arrest. To determine whether this would explain the resistance to TGF-binduced growth arrest, we asked whether overexpressing p21 in these cells, or alternatively prolonging the TGF-b signaling pathway in these cells by expressing a constitutively active version of ALK5, would be sufficient to cause a G 1 cell cycle arrest.
PT45 and Panc-1 cells were transfected with HAtagged p21 (HA-p21) which is readily distinguished (Figure 6d , panels i and ii). This was specific for p21 overexpression, since in control experiments, expression of the bacterial repressor protein LexA had no effect on the distribution of cells in the different phases of the cell cycle (data not shown). Overexpressing an HA-tagged constitutively active derivative of ALK5 (ALK5 * ; Wieser et al., 1995) had a similar effect to overexpressing p21 in these cells. The expression of HA-ALK5 * induced a strong shift in the G 1 populations from 55 to 79% and 58 to 75% in the transfected PT45 and Panc-1 cells, respectively (Figure 6d , panels iii and iv).
Thus, when p21 is expressed at sustained levels in PT45 and Panc-1 cells, or when the TGF-b signaling pathway is prolonged by expression of activated ALK5, these cells do undergo cell cycle arrest in G 1 .
Continuous TGF-b signaling for 12-14 h is required for TGF-b-induced growth arrest in HaCaT cells
The data presented above strongly suggest that the attenuated TGF-b-Smad signaling pathway in PT45 and Panc-1 cells is responsible for the resistance to TGF-binduced growth arrest in these cells. We directly tested this idea by artificially attenuating the TGF-b-Smad signaling pathway in HaCaT cells and investigating whether this then led to a loss of TGF-b-induced growth arrest in these cells.
The TGF-b signaling pathway was therefore terminated in HaCaT cells at different times after TGF-b addition, and the effect of this on the ability of TGF-b to induce cell cycle arrest was investigated. To terminate the TGF-b signaling pathway, we used the wellcharacterized highly selective ALK5 inhibitor, SB-431542 (Callahan et al., 2002) . We have previously demonstrated that this inhibitor is potent and specific and acts almost immediately after addition to inhibit ALK5 kinase activity and prevent Smad2 and 3 phosphorylation (Inman et al., 2002a) , and therefore accumulation of active Smad2/3 in the nucleus (Figure 7a; Inman et al., 2002b) .
Treatment of the cells with SB-431542 at the same time as TGF-b inhibited TGF-b-induced G 1 cell cycle arrest as expected (Figure 7b ). Allowing the receptors to signal for 4 h (i.e. SB-431542 was added 4 h after TGFb) was not sufficient to cause a cell cycle arrest at the 26-h time point (Figure 7b) . Even 12 h of continuous TGFb signaling was not sufficient for TGF-b-induced growth arrest (Figure 7b ). However, allowing the receptors to signal for 14 h was sufficient to induce growth arrest. This experiment demonstrates that continuous receptor activation for between 12 and 14 h is required for TGF-b to induce a G 1 cell cycle arrest, and demonstrates directly that attenuation of the signaling pathway confers resistance to the antiproliferative effects of TGF-b. This results in a failure to accumulate p21 mRNA or protein, and subsequently to downregulate Cdc25A mRNA in PT45 and Panc-1 cells. We conclude that this can account for the loss of TGF-b-induced growth arrest, since we demonstrate that either prolonging the TGF-b signaling pathway by overexpressing constitutively active ALK5, or overexpressing p21, is sufficient to induce cell cycle arrest in G 1 in these cells. Moreover, this view is strongly supported by the demonstration that premature termination of the TGF-b signaling pathway in HaCaT cells by specific inhibition of the ALK5 kinase activity is sufficient to prevent these cells arresting in G 1 .
Mechanism of attenuation of the TGF-b-Smad signaling pathway in tumor cells
Our data suggest that the low level of TbRI/ALK5 in PT45 and Panc-1 cells may be responsible for the attenuation of the TGF-b-Smad signaling pathway in these cells. The current view is that TGF-b signaling is terminated by degradation of the active receptor complex. This occurs through the recruitment of the E3 ubiquitin ligase Smurf2 and/or Smurf1 to the activated receptors via Smad7 which results in degradation of Smad7 and the receptors via the proteasomal and lysosomal pathways (Kavsak et al., 2000; Ebisawa et al., 2001) . In Mv1Lu cells both endogenous receptors are substantially downregulated 4 h after TGF-b stimulation (Kavsak et al., 2000) . Since there are low levels of type I receptor in PT45 and Panc-1 cells, they would be degraded to a level below that required for active signaling more rapidly than receptors in other cell lines which are expressed at higher levels, assuming similar rates of degradation. The levels of type II receptors in these cells may also be important for determining the duration of Smad signaling, but attempts to accurately determine the levels of type II receptor protein in these cells using the available antibodies were unsuccessful HaCaT cells were either untreated or treated with 2 ng/ml TGF-b1 and 10 mm of the specific ALK5 inhibitor, SB-431542 dissolved in DMSO or with 2 ng/ml TGF-b1 and DMSO. Samples were processed for indirect immunofluorescence using an anti-Smad2/3 antibody and examined by confocal laser scanning microscopy. owing to the substantial crossreactivity of these antibodies with other cellular proteins. In addition, increased levels of Smad7 and/or Smurf1 and 2 could contribute to the more rapid termination of the signaling pathway in PT45 and Panc-1 cells. We have been unable to measure levels of the Smurfs due to the lack of suitable antibodies. However, in Panc-1 cells, though not in PT45 cells, Smad7 is highly expressed, and could contribute to the attenuation of Smad signaling in these cells. Interestingly, overexpression of Smad7 in Colo-357 cells leads to loss of TGF-b-induced growth arrest, but has no effect on TGF-b-induced activation of PAI-1 transcription (Kleeff et al., 1999) . How could low levels of receptor in PT45 and Panc-1 cells elicit only a transient accumulation of active Smads in the nucleus? In a separate study, we have demonstrated that continuous signaling from the TGF-b receptors is required to maintain the presence of active Smad complexes in the nucleus (Inman et al., 2002b) . We have demonstrated that while the receptors remain active, Smad2, 3 and 4 are actively cycling between the nucleus and the cytoplasm. In the nucleus Smad2 and 3 are constantly being dephosphorylated, which causes them to dissociate from Smad4 and return to the cytoplasm. There they are rephosphorylated by the receptors if they are still active, form complexes with Smad4 and re-enter the nucleus. If the receptors are no longer active (for instance, if they have been downregulated by degradation; Kavsak et al., 2000; Ebisawa et al., 2001) , the R-Smads become rapidly dephosphorylated and accumulate back in the cytoplasm together with Smad4. Thus, the Smads are constantly monitoring the levels of activated receptor, and the overall time that the active Smads reside in the nucleus will reflect the time that the receptors remain active. We have demonstrated that the receptors remain active for greater than 4 h in HaCaT cells (Inman et al., 2002b) , and in agreement with this, the active Smads remain nuclear in these cells for at least 6 h (Figure 4) . If the time taken for receptor levels to fall below a threshold for active signaling, however, is curtailed due to low receptor levels, as in the PT45 and Panc-1 cells, then clearly the time that the active Smads remain nuclear will be similarly diminished.
The time that the active Smad complexes remain nuclear influences the transcriptional responses to TGF-b
We have demonstrated that the cell lines that display an attenuated TGF-b signaling pathway show an altered pattern of expression of target genes, when compared with cells which exhibit more prolonged TGF-b signaling. It is clear that some genes are much more affected than others. In particular, inductions of p21, JunB and the downregulation of Cdc25A are severely affected, while inductions of PAI-1, c-Jun and Smad7 in PT45 and Panc-1 cells are more or less comparable with those seen in HaCaT and Colo-357 cells. Thus, genes involved in growth arrest, such as p21, JunB and Cdc25A are very sensitive to the time that active Smads remain in the nucleus.
The idea that different strengths of signal could lead to different concentrations of Smads in the nucleus, regulating particular sets of target genes has been established for Activin/Nodal signaling and BMP signaling in the early Xenopus embryo (Wilson et al., 1997; Shimizu and Gurdon, 1999; Gurdon and Bourillot, 2001; Hill, 2001) . The affinity of active Smad complexes for particular promoter sequences and/or transcription factors bound to these promoters may be a mechanism whereby distinct promoters could be regulated by different concentrations of Smads (Hill, 2001 ). In the pancreatic tumor cells, PT45 and Panc-1, the failure to activate expression of JunB, which normally occurs rapidly after TGF-b addition, may be due to lower levels of nuclear Smads in these cells, and not necessarily due to the shortened time that the active Smads reside in the nucleus. However, we propose that the failure to sustain high levels of p21 mRNA and protein in these cells is a direct result of the very transient accumulation of the active Smads in the nuclei. Since p21 protein has a short half-life (B1 h) (Touitou et al., 2001) , it is necessary to sustain its production in response to TGF-b throughout the G 1 phase of the cell cycle so that it can inhibit both cyclin D-CDK4/6 complexes early in G 1 and cyclin E-CDK2 complexes later in G 1 to elicit a cell cycle arrest (Sherr and Roberts, 1999; Massague´et al., 2000) . Cdc25A downregulation is a secondary response to TGF-b, and is a consequence of inhibition of cyclin-CDK complexes by CDK inhibitors (Iavarone and Massague´, 1999) . It is likely therefore that the absence of TGF-b-induced Cdc25A downregulation in PT45 and Panc-1 cells results indirectly from the lack of p21 induction. Although the resistance to TGF-b-induced growth arrest in Panc-1 and PT45 cells may be explained by the lack of p21 upregulation and Cdc25A downregulation, we do not rule out that other genes could also be involved.
In contrast to the genes involved in cell cycle arrest, the other genes (PAI-1, c-Jun and Smad7), which have all been implicated in tumor promotion (see Introduction) are relatively insensitive to the attenuated TGF-b signaling pathway exhibited by PT45 and Panc-1 cells, suggesting that they require only transient low levels of active Smads for their induction. Interestingly, similar mechanims of TGF-b induction have been proposed for these three genes (Dennler et al., 1998; Hua et al., 1998; Wong et al., 1999; Denissova et al., 2000; Hua et al., 2000) . In all cases TGF-b-induced transcription requires Smad3/Smad4 complexes bound to Smad binding elements in conjunction with other transcription factors (AP1 family members in the case of c-Jun (Wong et al., 1999) , and TFE3 in the case of Smad7 and PAI-1 (Hua et al., 1998 (Hua et al., , 2000 ).
Is the attenuation of the TGF-b-Smad signaling pathway a common mechanism by which cancer cells evade the antiproliferative effects of TGF-b?
In this paper we have shown that an attenuated TGF-bSmad signaling pathway leads to resistance to TGF-binduced growth arrest, while having little effect on other TGF-b responses as measured by target gene activation. We propose that low levels of TbRI/ALK5 could be responsible for the rapidly downregulated pathway. We speculate that this may be a fairly common mechanism whereby tumor cells specifically become resistant to TGF-b-induced growth arrest, while remaining responsive to TGF-b's pro-oncogenic activities, since in many different tumor cells expression of either TbRII or TbRI/ALK5 is downregulated. This has been shown to result from altered levels of Ets transcription factors required for the expression of TbRII, hypermethylation of CpG islands in TbRI/ALK5 or TbRII gene promoters or from mutations in the promoter of TbRII that impair transcription factor binding Derynck et al., 2001; Jonson et al., 2001) . Our current results indicate that an important determinant of the biological response to TGF-b is the time that the active Smad complexes remain nuclear after TGF-b stimulation, and we propose that the levels of TGF-b receptors could dictate this.
Material and methods
Plasmids
The p21 CIP1/WAF1 coding sequence was subcloned into an EF-HA expression vector. EF-NLex(1-202) was as described (Price et al., 1996) . The HA-tagged constitutively active version of ALK5 (Wieser et al., 1995) was a gift from Anita Roberts.
Cell lines, transfection and cell cycle analysis
All cell lines used were grown in DMEM/10% FCS, except for Colo-357, SW-979 and BxPC3 cell lines which were grown in RPMI/10% FCS. PT45 and Panc-1 cell lines were transfected with LipofectAMINE (Invitrogen). At 24 h after transfection, cells were fixed with 1% paraformaldehyde in PBS for 15 min and refixed with 70% ethanol. Cells were then incubated with anti-HA anti-LexA antibodies in 10% BSA/0.3% Triton/PBS, washed in 0.1% Triton/PBS, then incubated with an FITC-conjugated secondary antibody for another 10 min. After a further two washes, cells were treated with RNase A (100 ng/ml), then stained with 50 mg/ml of propidium iodide and analysed by flow cytometry.
For cell cycle analysis of untransfected cells, cells growing at low density (40%) in normal growth medium were treated with 2 ng/ml of TGF-b1 (PeproTech), or serum starved for times shown in the legend to Figure 1 , then analysed for cell cycle distribution as above. For inhibition of ALK5 activity, SB-431542 was used as described (Inman et al., 2002a) .
Western blotting and bandshift assays
For the Western blot shown in Figure 5 , whole cell extracts were prepared using RIPA buffer (Harlow and Lane, 1988) to maximize the extraction of the type I receptors. For all other Western blots, whole cell extracts were prepared as described (Inman et al., 2002a) . Nuclear extracts were prepared as described (Wong et al., 1999) . The following antibodies were used, anti-Smad2 (which also recognizes Smad3), anti-GRB2 and anti-E-cadherin (Transduction Laboratories), antiSmad4 (B8; Santa Cruz), anti-p21 (C19; Santa Cruz) and anti-TbRI/ALK5 (V22; Santa Cruz), anti-Smad3 (Zymed), anti-phosphorylated Smad2 (Faure et al., 2000) , anti-Smad7 (Kavsak et al., 2000) , anti-vimentin (V3B; Boehringer Mannheim), anti-pRb (Pharmingen), anti-PCNA (Howell et al., 1999) and anti-LexA (ICRF in-house polyclonal antibody raised against the peptide MKAKTARQQEVFDLIRDHISQT). Bandshift assays using nuclear extracts and the probe corresponding to the SBE from the c-jun 5 0 UTR were as described (Lehmann et al., 2000) .
RNA isolation and RNase protections
Cells grown to a 70-80% density were stimulated with TGF-b1 at different times. Cells were lysed and extraction of RNA, probe preparation and RNase protection assays were performed as described (Howell and Hill, 1997; Pierreux et al., 2000) . Fragments from the following genes (indicated as amino acid number in the protein sequence) were used as probes: Smad7 (amino acids 2-163), Cdc25A (amino acids 321-424), JunB (amino acids 42-108), p21 CIP1/WAF1 (amino acids 1-163), PAI-1 (amino acids 25-141) and p15 INK4B (amino acids 1-87). The probe for c-jun protects 146 nucleotides in the 5 0 UTR from position +288 to +433 and the probe for g-actin was as described (Enoch et al., 1986) .
Confocal fluorescence microscopy and light microscopy
Detection of Smad2/3, Smad4, p21 or HA by immunostaining was as described . All the antibodies used are described above except that for HA, which was a rat monoclonal antibody (Boehringer Mannheim). For the detection of E-cadherin and vimentin, cells were fixed in methanol/acetone 1:1 at À201C for 5 min, then washed three times in PBS and blocked with 0.2% fish gelatine in PBS. Anti-E-cadherin or vimentin antibodies (as above) were used at a dilution of 1 in 200. Subsequent washes and secondary antibody application were as above. In all cases, samples were analysed immediately using a Zeiss confocal LSM 510 microscope, except for those shown in Figure 6c , which were visualized using a Zeiss Axioplan 2 fluorescent microscope. 
